Related Experiment Video
Updated: Aug 17, 2025
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
Expression of inducible factors reprograms CAR-T cells for enhanced function and safety
Anže Smole1, Alexander Benton2, Mathilde A Poussin3
1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety remain. Investigators have begun to enhance CAR-T cells with the expression of accessory molecules to address these challenges. Current systems rely on constitutive transgene expression or multiple viral vectors, resulting in unregulated response and product heterogeneity. Here, we develop a genetic platform that combines autonomous antigen-induced production of an accessory molecule with constitutive CAR expression in a single lentiviral vector called Uni-Vect. The broad therapeutic application of Uni-Vect is demonstrated in vivo by activation-dependent expression of (1) an immunostimulatory cytokine that improves efficacy, (2) an antibody that ameliorates cytokine-release syndrome, and (3) transcription factors that modulate T cell biology. Uni-Vect is also implemented as a platform to characterize immune receptors. Overall, we demonstrate that Uni-Vect provides a foundation for a more clinically actionable next-generation cellular immunotherapy.
Insights
A novel Uni-Vect platform enhances CAR-T cell therapy by enabling antigen-induced accessory molecule production. This improves cancer immunotherapy efficacy and safety by controlling T-cell responses.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Chimeric antigen receptor T (CAR-T) cell therapy shows promise in cancer immunotherapy but faces challenges in efficacy and safety.
- Current methods for enhancing CAR-T cells often involve constitutive transgene expression or multiple viral vectors, leading to uncontrolled responses and product variability.
Purpose of the Study:
- To develop a novel genetic platform, Uni-Vect, for enhanced CAR-T cell immunotherapy.
- To enable autonomous, antigen-induced production of accessory molecules in CAR-T cells using a single lentiviral vector.
Main Methods:
- Development of a single lentiviral vector (Uni-Vect) for constitutive CAR expression and autonomous accessory molecule production.
- In vivo validation of Uni-Vect's ability to express immunostimulatory cytokines, ameliorating antibodies, and transcription factors dependent on antigen activation.
Main Results:
- Uni-Vect demonstrated activation-dependent expression of beneficial molecules in vivo, including cytokines for improved efficacy and antibodies to mitigate cytokine-release syndrome.
- The platform successfully modulated T cell biology through transcription factor expression.
- Uni-Vect was also utilized as a tool for characterizing immune receptors.
Conclusions:
- Uni-Vect provides a robust platform for next-generation cellular immunotherapies, offering greater control over T cell responses.
- This system enhances the clinical applicability of CAR-T cell therapy by improving safety and efficacy profiles.
Related Concept Videos
01:29Somatic to iPS Cell Reprogramming
01:13Induced Pluripotent Stem Cells